key: cord-0808977-q8ubqj6w authors: Kashiwagi, Katsuhito; Ishii, Yoshikazu; Aoki, Kotaro; Yagi, Shintaro; Tadashi, Maeda; Miyazaki, Taito; Yoshizawa, Sadako; Aoyagi, Katsumi; Tateda, Kazuhiro title: Immunochromatographic test for the detection of SARS-CoV-2 in saliva date: 2020-12-23 journal: J Infect Chemother DOI: 10.1016/j.jiac.2020.11.016 sha: 703ad4f90bfeb82e627c419aa96f770fd2500290 doc_id: 808977 cord_uid: q8ubqj6w We evaluated the rapid immunochromatographic test for severe acute respiratory coronavirus 2 (SARS-CoV-2) antigen detection using 16 saliva specimens collected from 6 COVID-19 hospitalized patients, and detected N-antigen in 4 of 7 RT-PCR positive specimens. This POCT detected SARS-CoV-2 antigen in saliva and would be useful for COVID-19 diagnosis.. Respiratory disease (COVID-19) caused by 2019 novel coronavirus, severe acute respiratory coronavirus 2 (SARS-CoV-2), is diagnosed by nucleic acid amplification test, as reverse transcription polymerase chain reaction (RT-PCR), for viral genome RNA in nasopharyngeal swab specimens. The collection procedure of nasopharyngeal specimens poses a risk of secondary infection to health-care workers. The risk could be reduced if saliva specimens could be used for diagnosis of COVID-19. Recently, several reports indicated that SARS-CoV-2 was detected in saliva specimens of equally or higher sensitivity than the nasopharyngeal specimens [1] [2] [3] [4] . A rapid antigen detection kit, ESPLINE ® SARS-CoV-2 reagent (Fujirebio Inc., Tokyo), for detection of the viral N antigens in nasopharyngeal swabs was recently developed [5] . The ESPLINE test is an enzyme-immunoassay based on immunochromatographic technology using monoclonal antibodies specific to SARS-CoV and CoV-2 N antigens. In this report, we evaluated the saliva specimens for diagnosis of COVID-19 by RT-PCR and the point of care testing (POCT) antigen test. Sets of saliva and nasopharyngeal specimens were collected within several days from 6 COVID-19 patients hospitalized in Omori Hospital, who had been diagnosed by RT-PCR test. The study protocol was approved by the Ethics Committee of Faculty of Medicine, Toho University (No. A20028_A20020_A20014_A19099). Informed consent was obtained from all participants in the study. Saliva was collected by passive drool method according to previous report [6, 7] . Nasopharyngeal swab specimens were collected directly following the ESPLINE kit manufacturer's instructions except for 4 cases, in which the swab specimens were resuspended in universal virus transport medium (UVT). The specimen-treatment solution supplied with the kits was used for assay of both kit's swab and saliva specimens and the assays were performed following the kit manufacturer's instructions. Ct values were obtained by RT-PCR test using N2 probe according to the manual provided by National Institute of Infectious Diseases. SARS-CoV-2 antigen was assessed using ESPLINE kit according to the manufacturer's instruction. All assays were carried out on the day of specimen collection. On the other hand, RT-PCR detected RNA in only 7 of 16 saliva specimens (43.8%). Following exclusion of the 4 nasopharyngeal specimens that had been suspended in UVT, 7 of the remaining 9 (77.8% sensitivity) were positive by the ESPLINE test. The antigen was detected in 4 of 7 RT-PCR positive saliva specimens (47.8%) (Figure 1 ). The sensitivity of the antigen test seems to depend on the RNA-copy concentrations in the specimens; however, no significant difference was observed (Figure 1 ). Sensitivity of SARS-CoV-2 RT-PCR in saliva specimens was lower than those reported previously [1, 2, 4, [8] [9] [10] . Among several procedures of saliva collection which have been applied, we chose the passive drool method to reduce the burden of the patients and the secondary risk to healthcare workers. However, collection procedure should be examined for further studies. In addition, symptoms, periods after the onset of symptoms and infection could affect the sensitivity of the RNA detection in saliva. These factors would also affect the sensitivity of antigen detection using the ESPLINE kit. This study was carried out using specimens collected from hospitalized patients. The patients. An extensive evaluation of rapid antigen testing using saliva samples would require additional studies using a variety of specimens collected from a larger number of patients. The combination of saliva specimen and rapid antigen detection test could reduce burden of medical settings by decreasing not only the risk of secondary infection, but also time of diagnosis and cost of the specialized expensive equipment. A saliva-antigen test would be useful in ordinal clinics to identify persons with high-viral loads. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 nasopharyngeal swabs Saliva Sample as a Non-Invasive Specimen for the Diagnosis of Coronavirus Disease-2019 (COVID-19): a Cross-Sectional Study Saliva as a non-invasive specimen for detection of SARS-CoV-2 Development of Rapid lmmunochromatographic Enzyme lmmunoassay for SARS-CoV-2 Nucleocapsid protein Development of Genetic Diagnostic Methods for Novel Coronavirus 2019 (nCoV-2019) in Japan Manual for the Detection of Pathogen 2019-nCoV Ver.2.9 Consistent detection of 2019 novel coronavirus in saliva Continuously High Detection Sensitivity of Saliva, Viral Shedding in Salivary Glands and High Viral Load in Patients with COVID-19 Detection of 2019-nCoV in Saliva and Characterization of Oral Symptoms in COVID-19 Patients